- Home
- PPBT
PPBT
Purple Biotech Ltd.
as 03-28-2025 4:00pm EST
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
| Founded: | 2010 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.1M | IPO Year: | N/A |
| Target Price: | $33.00 | AVG Volume (30 days): | 13.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $20.60 | Next Earning Date: | 03-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Purple Biotech Ltd. News
PPBT Breaking Stock News: Dive into PPBT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
GlobeNewswire
21 days ago
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
a month ago
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
GlobeNewswire
a month ago
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
GlobeNewswire
2 months ago
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
GlobeNewswire
4 months ago
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire
4 months ago
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire
4 months ago
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Compare PPBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PPBT Purple Biotech Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.